MAPT and supranuclear palsy, progressive, 1: To further understand the association of the TauRD interacting partners to disease, we integrated the tau interactome data with previously generated proteomics data from human post-mortem bulk frontal cortex samples74, including control (CTL, n=46), Alzheimer’s disease (AD, n=49), and progressive supranuclear palsy (PSP, n=26) (Fig. 5A, Supplemental Table 9).